Jeffrey A. Engelman, Ph.D.

2000 Yeshiva University, New York, NY, United States 
Molecular Biology, Pharmacology
"Jeffrey Engelman"
Mean distance: 6635.5


Sign in to add mentor
Michael P. Lisanti grad student 2000 Yeshiva University
 (The roles of caveolin-1 and MAP kinase pathways in cellular transformation and differentiation.)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Palmer AC, Plana D, Gao H, et al. (2020) A proof of concept for biomarker-guided targeted therapy against ovarian cancer based on patient-derived tumor xenografts. Cancer Research
Bialucha CU, Collins SD, Li X, et al. (2017) Discovery and Optimization of HKT288, a Cadherin-6 Targeting ADC for the Treatment of Ovarian and Renal Cancer. Cancer Discovery
Heist RS, Sequist LV, Borger D, et al. (2016) Acquired Resistance to Crizotinib in Non-small Cell Lung Cancer with MET exon 14 skipping. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer
Shaw AT, Engelman JA. (2016) Crizotinib Resensitization by Compound Mutation. The New England Journal of Medicine. 374: 1790-1
Heist RS, Shim HS, Gingipally S, et al. (2016) MET Exon 14 Skipping in Non-Small Cell Lung Cancer. The Oncologist
Koyama S, Akbay EA, Li YY, et al. (2016) Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nature Communications. 7: 10501
Katayama R, Sakashita T, Yanagitani N, et al. (2016) P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer. Ebiomedicine. 3: 54-66
Ham J, Costa C, Sano R, et al. (2016) Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination. Cancer Cell. 29: 159-72
Breitkopf SB, Yang X, Begley MJ, et al. (2016) A Cross-Species Study of PI3K Protein-Protein Interactions Reveals the Direct Interaction of P85 and SHP2. Scientific Reports. 6: 20471
Hata AN, Niederst MJ, Archibald HL, et al. (2016) Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nature Medicine
See more...